Psyence Group

About Psyence Group

This author has not yet filled in any details.
So far Psyence Group has created 23 blog entries.

Optimi Health and Psyence Biomedical Sign Non-Binding Letter of Intent to Advance Global Psilocybin Drug Development

2024-08-27T10:00:50+02:00August 13, 2024|Investor Information, Press Releases, Psychedelic News|

Psyence Biomed today announced the export of nature-derived psilocybin to Australia and provided an update on its upcoming Phase IIb clinical trial evaluating nature‑derived psilocybin as a potential treatment for Adjustment Disorder following an advanced cancer diagnosis in the Palliative Care context.

Psyence Biomed Enters Into $25 Million Common Stock Purchase Agreement with White Lion Capital, LLC

2024-08-27T09:55:48+02:00August 2, 2024|Investor Information, Press Releases, Psychedelic News|

Psyence Biomed today announced the export of nature-derived psilocybin to Australia and provided an update on its upcoming Phase IIb clinical trial evaluating nature‑derived psilocybin as a potential treatment for Adjustment Disorder following an advanced cancer diagnosis in the Palliative Care context.

Psyence Biomed Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial

2024-08-27T14:01:21+02:00July 25, 2024|Investor Information, Press Releases, Psychedelic News|

Psyence Biomed today announced the export of nature-derived psilocybin to Australia and provided an update on its upcoming Phase IIb clinical trial evaluating nature‑derived psilocybin as a potential treatment for Adjustment Disorder following an advanced cancer diagnosis in the Palliative Care context.

Psyence Biomed Announces Phase IIb Clinical Trial Listing on the Australian New Zealand Clinical Trials Registry (ANZCTR)

2024-08-27T09:58:34+02:00April 18, 2024|Investor Information, Press Releases, Psychedelic News|

Psyence Biomedical Ltd (Nasdaq:PBM) (“Psyence Biomed” or the “Company”) today announced that details of its upcoming Phase IIb clinical trial of nature-derived psilocybin in patients diagnosed with Adjustment Disorder following an advanced cancer diagnosis in the Palliative Care context has been listed on the Australian New Zealand Clinical Trials Registry (“ANZCTR”), under registration number 12624000449538p. The randomized, double-blind, placebo-controlled Phase IIb study will test three doses (25mg, 10mg and 1mg) of nature-derived psilocybin in 84 patients in conjunction with psychotherapy. Psyence Biomed anticipates enrolling the first subject in the second quarter of 2024 and expects the primary endpoint results to be available in 2025.

Psyence Biomed Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial

2024-08-27T10:00:45+02:00April 9, 2024|Investor Information, Press Releases|

has entered into a partnership with Fluence, a global leader in professional education and training for psychedelic therapy research, and iNGENū CRO Pty Ltd (“iNGENū”), an Australian clinical research organization (CRO), to support an upcoming Phase llb clinical trial. The trial will explore the efficacy and safety of psilocybin-assisted psychotherapy (PAP) for the treatment of Adjustment Disorder due to a recent cancer diagnosis in the Palliative Care context.

  • Psyence Biomedical’s Subsidiary, Psyence Australia, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study

Psyence Biomedical’s Subsidiary, Psyence Australia, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study

2024-08-27T10:12:14+02:00March 7, 2024|Investor Information, Press Releases, Psychedelic News|

Psyence Australia (Pty) Ltd ("Psyence Australia"), has received full approval from the Australian Health Research Ethics Committee (HREC) to initiate its planned Phase IIb study in Melbourne, Australia. The study will examine the use of nature-derived psilocybin as a treatment for Adjustment Disorder due to a recent cancer diagnosis in the palliative care context.

Go to Top